Nutriband (NASDAQ:NTRB) Announces Earnings Results

Nutriband (NASDAQ:NTRB) released its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, Zacks reports. Nutriband had a negative return on equity of 106.75% and a negative net margin of 448.25%.The firm had revenue of $0.43 million during the quarter.

Nutriband Stock Down 3.7%

Shares of NASDAQ:NTRB opened at $3.39 on Friday. Nutriband has a 1 year low of $3.21 and a 1 year high of $11.68. The company has a market cap of $41.22 million, a PE ratio of -1.31 and a beta of 1.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.36 and a quick ratio of 6.21. The stock’s 50-day moving average is $3.75 and its 200 day moving average is $4.17.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Nutriband from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Nutriband stock. Vanguard Group Inc. boosted its holdings in shares of Nutriband Inc. (NASDAQ:NTRB) by 1.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 202,738 shares of the company’s stock after purchasing an additional 3,111 shares during the period. Vanguard Group Inc. owned about 1.68% of Nutriband worth $1,429,000 at the end of the most recent reporting period. 19.70% of the stock is owned by institutional investors and hedge funds.

About Nutriband

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.